Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, multicenter, multicountry study to evaluate the effectiveness of Florbetapir (18F) PET imaging in changing patient management and to evaluate the relationship between Florbetapir (18F) PET status and cognitive decline.

Trial Profile

A randomized, multicenter, multicountry study to evaluate the effectiveness of Florbetapir (18F) PET imaging in changing patient management and to evaluate the relationship between Florbetapir (18F) PET status and cognitive decline.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Florbetapir F 18 (Primary)
  • Indications Alzheimer's disease; Dementia
  • Focus Diagnostic use
  • Sponsors Avid Radiopharmaceuticals
  • Most Recent Events

    • 22 Jul 2015 According to an Eli Lily media release, data from this study were presented today at the Alzheimer's Association International Conference 2015 (AAIC).
    • 22 Jul 2015 Results published in an Eli Lily media release.
    • 30 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top